drugset / Trial / NCT07057271
A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
Phase 3
Completed
464 enrolled
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients with Type 2 Diabetes with Inadequately Controlled Blood Glucose Level after Metformin Monotherapy or Metformin in Combination with Insulin Secretagogues.
Timeline
- Start
- 2021-05-27
- Primary completion
- 2023-02-21
- Completion
- 2023-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CJC-1134-PC | Unknown | 2 mg | — |